RXST stock holds as RxSight advances its light-adjustable lens business

RxSight, Inc. (US78419L1008) is supported by a 2024 revenue base of $119.2 million, up 23.6% from $96.4 million in 2023, while gross margin was 36.4% for the year. The company also ended 2024 with cash, cash equivalents and investments of $335.4 million, according to its annual filing.

Revenue grew 23.6%

In its 2024 annual report, RxSight said revenue reached $119.2 million, compared with $96.4 million in 2023. That 23.6% increase is the clearest operating metric available in the latest published financials and shows that sales momentum continued to build through the year.

Gross margin improved to 36.4% in 2024, and management reported cash, cash equivalents and investments of $335.4 million at year-end. Those figures matter more than a short-term headline because they frame both execution and balance-sheet flexibility around the company's next commercial phase.

Cash and margin matter

RxSight also reported an operating loss of $93.9 million in 2024, versus an operating loss of $92.1 million in 2023. Net loss widened to $92.7 million from $91.4 million a year earlier, which means the company is still funding growth while scale remains below profitability.

The numbers point to a business that is still in expansion mode rather than harvest mode. For investors, the combination of $119.2 million in annual revenue, 36.4% gross margin and $335.4 million in liquidity is more useful than a narrative based on one trading session.

Light-adjustable lens focus

RxSight's core commercial product is the Light Adjustable Lens platform, which sits at the center of the company's revenue model. The product is the main reason the market tracks installed-base growth, procedure adoption and surgeon utilization as the relevant operating signals.

That product focus matters because the company is not a diversified medtech conglomerate. Its financial profile is therefore more sensitive to adoption of the lens platform than to broad hospital purchasing cycles.

Trading level framework

No current quote is included here, so the most recent durable market reference in this article remains the 2024 financial backdrop and the company's capitalization context embedded in its filing. RXST stock should be read against the company's revenue growth, gross margin and cash balance rather than against a headline-only move.